Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAP1-6D Vaccine in Pancreatic Cancer
NCT00203892Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Apr 2003
- Primary completion
- Jun 2009
- Modality
- Prophylactic Vaccines, Peptides, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CEA peptide 1-6D in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by University of Chicago. Primary endpoint: Maximum T Cell Response From Baseline. Started Apr 2003; status: completed.
02
Drugs
CEA peptide 1-6D
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00203892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203892.